Over the past 12 months, NovaBridge Biosciences insiders bought $577,300 of stock on the open market (230K shares) and sold $154,273 (157.34K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Cong Claire Xu | Evp, Clinical Development | 304,201 | 0 | 304,201 | 30.3% | 01 Sep, 2026 |
| 2 | Sean Wuxiong Cao | Chief Bus. Development Officer | 266,467 | 0 | 266,467 | 26.5% | 11 Sep, 2026 |
| 3 | Mark Arnold Hagler | Officer | 230,000 | 0 | 230,000 | 22.9% | 28 Apr, 2026 |
| 4 | Phillip Andrew Dennis | Chief Medical Officer | 173,427 | 0 | 173,427 | 17.3% | 21 Sep, 2026 |
| 5 | Robert A. Lenz | Director | 17,218 | 0 | 17,218 | 1.7% | 25 Aug, 2026 |
| 6 | Ian Ying Woo | Director | 13,271 | 0 | 13,271 | 1.3% | 19 Oct, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 15 Oct, 2026 | Ian Ying Woo | Director | Acquired M | 13,271 | — | — | 13,271 | Direct |
| 15 Oct, 2026 | Ian Ying Woo | Director | Disposed M | 5,770 | $0.00 | $0 | 11,540 | Direct |
| 17 Sep, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Acquired M | 23,695 | — | — | 181,636 | Direct |
| 18 Sep, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Disposed S | 8,209 | $0.71 | $5.83K | 173,427 | Direct |
| 17 Sep, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Disposed M | 10,302 | $0.00 | $0 | 72,120 | Direct |
| 09 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Disposed S | 107,978 | $0.74 | $79.90K | 266,467 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Acquired M | 235,136 | — | — | 270,209 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Acquired M | 104,236 | — | — | 374,445 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Disposed M | 102,233 | $0.00 | $0 | 306,700 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Disposed M | 45,320 | $0.00 | $0 | 135,960 | Direct |
| 30 Aug, 2026 | Cong Claire Xu | Evp, Clinical Development | Acquired M | 9,382 | — | — | 307,483 | Direct |
| 31 Aug, 2026 | Cong Claire Xu | Evp, Clinical Development | Disposed S | 3,282 | $0.79 | $2.59K | 304,201 | Direct |
| 30 Aug, 2026 | Cong Claire Xu | Evp, Clinical Development | Disposed M | 4,079 | $0.00 | $0 | 28,558 | Direct |
| 22 Aug, 2026 | Robert A. Lenz | Director | Acquired M | 17,218 | — | — | 17,218 | Direct |
| 22 Aug, 2026 | Robert A. Lenz | Director | Disposed M | 7,486 | $0.00 | $0 | 14,974 | Direct |
| 08 Jul, 2026 | Mark Arnold Hagler | Chief Commercial Officer | Acquired A | 949,050 | $0.00 | $0 | 949,050 | Direct |
| 08 Jul, 2026 | Liwei Lorraine Lin | General Counsel | Acquired A | 254,780 | $0.00 | $0 | 254,780 | Direct |
| 06 Jul, 2026 | Srishti Gupta | Chief Executive Officer | Acquired A | 3,000,000 | $0.00 | $0 | 3,000,000 | Direct |
| 04 Jul, 2026 | Cong Claire Xu | Svp, Clinical Development | Acquired M | 12,432 | — | — | 302,586 | Direct |
| 06 Jul, 2026 | Cong Claire Xu | Svp, Clinical Development | Disposed S | 4,485 | $0.89 | $3.99K | 298,101 | Direct |